Karnataka’s Food Safety and Drugs Administration has cancelled 16 drug licences and suspended eight more as investigators trace the distribution network behind an alleged counterfeit-medicine racket uncovered last month, in one of the state’s largest pharmaceutical enforcement actions in recent memory. The suspended licences include that of a Pfizer C&F depot in Bengaluru Rural district, though the investigation centers on unauthorized repackaging of medicines, not on Pfizer’s own manufacturing operations.
How the Racket Was Uncovered
The case began with a raid on August 18, when the Karnataka FDA’s Drug Enforcement Wing searched a farmhouse in Kurubarakeranahalli, near Bidadi in Bengaluru South district. Officials said they found what appeared to be an unlicensed pharmaceutical repacking and relabelling operation running out of the property, seizing spurious drugs, repackaging machinery, and printing materials with a combined estimated value of roughly ₹5.05 crore.
What Was Actually Found
The seizure list points to an operation working at meaningful scale. Officials recovered 5,640 vials labelled Cefiavigent 2.5 Injection, valued at approximately ₹3.38 crore, along with 1,531 Hizlam injectable vials worth around ₹52.24 lakh. Investigators also found 470 Xavitaz vials, 264 Emblavei vials carrying Pfizer labels, 165 Zavicefta vials, and quantities of products labelled Tigynt IV, Tigvnet, Aztreo, and Trezam, alongside 30 boxes of expired medicines, an injection-filling machine, and forged labels and stamps. Notably, the products involved were largely injectable antibiotics used to treat serious bacterial infections, medicines where authenticity and potency carry direct life-or-death stakes for patients.
How the Counterfeiting Scheme Worked
“The investigation will follow the entire supply chain.”
— Srinivas K, Commissioner, Karnataka Food Safety and Drugs Administration
According to Srinivas K, preliminary investigation indicates that low-cost medicines were being procured from neighboring states, filled into new vials, and relabelled to resemble expensive, life-saving medicines, including products carrying the Pfizer brand name. Investigators also found a detail that would have been easy for an ordinary buyer to miss: QR and scanning codes printed on the suspected counterfeit labels that did not function when verified, a strong indicator the labels were fabricated rather than issued through any legitimate manufacturer’s tracking system.
The Licences Affected, and an Important Distinction on Pfizer
As the investigation expanded into the retailers and wholesalers allegedly connected to the racket’s distribution, the FDA cancelled 16 drug licences outright and suspended eight more, covering firms including Med Pharma, Surya Speciality Hospital, Sagar Pharma Unit-II, Vivantha Pharmaceuticals, Maruthi Medicals, Viva Pharma, and Hi-5 Pharma, alongside the Pfizer Ltd C&F depot at Kempalinganahalli in Nelamangala taluk.
It’s worth being precise about what that depot suspension does and doesn’t indicate. Nothing in the investigation as reported alleges that Pfizer itself manufactured or knowingly distributed counterfeit product; the counterfeit vials were relabelled by the unlicensed operation to falsely resemble Pfizer-branded medicines, a scheme that makes Pfizer’s brand a target of the fraud rather than a party to it. The depot’s licence suspension appears to be part of the broader supply-chain sweep as authorities trace how the counterfeit products moved through the distribution network, rather than a finding of wrongdoing specific to Pfizer’s own operations. Karnataka health officials have not indicated that Pfizer’s own manufacturing or genuine product distribution was compromised.
Legal Consequences and the Scope of the Investigation
A criminal case has been registered under the Drugs and Cosmetics Act, 1940. Counterfeit medicines fall under Section 17B of the Act as spurious drugs, and offences involving their manufacture, sale, stocking, or distribution carry serious penalties under Section 27, ranging from a minimum of ten years of rigorous imprisonment up to life imprisonment, in addition to fines. Officials say the investigation now spans six states as authorities work to trace the racket’s full supply chain, and earlier reporting has indicated the network may have supplied counterfeit products to more than 90 hospitals and clinics in Bengaluru, with several medical representatives also under scrutiny. Four people were arrested during the initial raid, with additional arrests following subsequent operations.
Part of a Broader Enforcement Pattern in Karnataka
This case is the latest in a sustained pattern of pharmaceutical enforcement activity in the state. In June alone, Karnataka’s drug administration conducted more than 2,500 inspections statewide, resulting in 133 drug licences suspended and 20 cancelled over violations of the Drugs and Cosmetics Act, alongside the seizure of substandard drugs worth more than ₹40 lakh. That broader enforcement pattern lands alongside a wider wave of regulatory scrutiny of India’s pharmaceutical and medical device supply chains this year, including ongoing national efforts to rationalise pricing and improve oversight of hospital consumables.
What Officials Are Telling Consumers
The Karnataka Health Department has urged the public to purchase medicines only from licensed pharmacies and against valid tax invoices, and to report suspicious packaging or QR codes that fail to scan properly to drug enforcement authorities. The department has also blocked the batch numbers and portal entries associated with the seized medicines to prevent any further sale or distribution, and samples from the seizure have been sent to laboratories to determine their chemical composition, sterility, and potency.
What Comes Next
The seized medicines, machinery, and printing materials are set to be produced before the JMFC Court in Bengaluru South as part of ongoing legal proceedings, while a Special Investigation Team continues working to map the racket’s full distribution network across the six states now under scrutiny. With injectable antibiotics at the center of the case, and the products’ authenticity still being verified in laboratory testing, the investigation’s outcome will likely shape how seriously India’s broader pharmaceutical supply chain treats gaps that allow counterfeit medicines to reach hospitals and patients undetected.